Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil

1Department of Medical Oncology, Dana-Farber Cancer Institute, and Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and 2Department of Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil